Список проголосовавших за комментарий " <ul><li><strong>ITEK</strong> -65.6% (announces top-line results of MATrX-1 did not achieve its primary endpoint of superiority in reduction of intraocular pressure compared with placebo at all 12 time points; will wait for the full results from MATrX-1)</li><li><strong>TKC</strong> -4.4% (following Turkish terrorist attack)</li></ul>"